Evotec SE (EVO) vs Twist Bioscience Corporation (TWST)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| EVO | TWST | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GS |
| Country | Germany | United States |
| Theme | contract-research-cdmo | life-science-tools |
| Price and returns | ||
| Last close | $1.52 | $145.25 |
| Return · 1 week | +7.04% | +3.92% |
| Return · 1 month | −4.40% | −19.13% |
| Return · 3 months | −22.45% | +64.03% |
| Return · year to date | −52.20% | +348.44% |
| Return · 1 year | −63.11% | +324.96% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −64.40% | −33.89% |
| 52-week high | $4.27 | $219.71 |
| 52-week low | $1.33 | $23.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $540.19M | $9.63B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $76.23K | $302.09M |
| Employees | 4,461 | 979 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 0.68× | 20.38× |
| Price to book | 0.66× | 18.67× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | n/a (negative EBITDA) |
| Enterprise value to revenue | 0.70× | 19.14× |
| PEG ratio | n/a (negative earnings) | — |
| Earnings per share · trailing | -0.64 | -2.23 |
| Profitability | ||
| Gross margin | 8.46% | 51.97% |
| Operating margin | −62.26% | −30.65% |
| Profit margin | −27.47% | −31.66% |
| Return on equity | −26.08% | −29.59% |
| Return on assets | −5.39% | −13.09% |
| Growth | ||
| Revenue growth | −16.20% | +23.20% |
| Balance sheet and payout | ||
| Debt / equity (%) | 71.50 | 24.36 |
| Current ratio | 2.33 | 2.67 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | — |
| Trend and volatility | ||
| RSI · 14 | 46.66 | 38.20 |
| ADX · 14 | 14.37 | 25.91 |
| 50-day average | $1.68 | $147.91 |
| 200-day average | $2.56 | $83.26 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.35% | 11.43% |
The full EVO analysis
Everything this table leaves out for Evotec SE: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the EVO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full EVO analysisThe full TWST analysis
Everything this table leaves out for Twist Bioscience Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TWST argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TWST analysis